231 Front Street, Lahaina, HI 96761 [email protected] 808.123.4567

Tag: Functional

Fusion IV Pharmaceuticals INC Finds Functional Medicine Can Help With COVID Care

Los Angeles, CA – ( NewMediaWire ) – October 12, 2020 –  Fusion IV Pharmaceuticals INC provides functional medicine care for many patients and is focused on providing high-quality care during the Covid-19 pandemic. Their functional medicine approach has helped to identify many new treatment methods that can boost a person’s health and provide a substantial barrier to infection.

The Functional Approach Applied by Fusion IV Pharmaceutical INC

Functional medicine is a unique branch of treatments that Fusion IV Pharmaceutical INC has helped expand over the years. It focuses heavily on managing a person’s health through natural changes, such as adjusting their diet and their exercise routines.

In this way, functional medicine provides a unique opportunity to strengthen a person’s immune system against Covid-19. The worst symptoms of this disease are found to occur in those with weaker bodies or underlying conditions. Fusion IV Pharmaceutical INC seeks to help those with these problems by making their bodies more substantial and more resistant to diseases.

And Fusion IV Pharmaceutical INC has pioneered many care methods to make this process more streamlined and efficient. By understanding these techniques, those who are at more risk during this pandemic can decrease their potential risk and avoid severe symptoms.

Methods Used By Fusion IV Pharmaceuticals INC

At Fusion IV Pharmaceuticals INC, patients are being asked to follow the basic COVID prevention methods. These include social distancing – staying six feet away from others at all times – and washing and sanitizing hands whenever possible. Washing hands with soap for up to 20-30 seconds can help to kill many germs, including the COVID virus.

Fusion IV Pharmaceuticals INC is also creating dietary plans for patients that include healthy and unprocessed foods, cutting down on starches and unhealthy grains, and focusing on medicinal foods like spinach, cabbage, oranges, olives, and apples. These foods have flavonoids that help fight viruses, including kaempferol, hesperidin, and quercetin.

And Fusion IV Pharmaceuticals INC also provides immune-boosting treatments to help fight Covid and other conditions. These treatments include various types of supplements, such as 1,000-2,000 mg of Vitamin C, 20 mg of Zinc a day, 1-2 mg of sustained-released melatonin, and 1,200 mg of NAC every day. These supplements help keep the immune system functional and healthy.

Fusion IV Pharmaceuticals INC implements breakthrough techniques and delivery methods to enhance supplemental delivery. These include multiple infusion methods that work supplements directly into the bloodstream, making their delivery more comprehensive. Those who cannot tolerate this type of care may receive oral supplements that they can take at home.

About Fusion IV Pharmaceuticals INC

Fusion IV Pharmaceuticals INC is a compounding pharmacy that focuses on functional medicine, a patient-centered approach, and science-based care. Located in Los Angeles, California, they have helped promote wellness, better health, and medical science advances for over five years. They are led by Dr. Navid Vahedi, a passionate compounding pharmacist.

Source Article

SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual …

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) — SEnginePrecision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor organoids, today announced that Chief Medical Officer Astrid L. Margossian, MD, PhD, will present at the Society for Functional Precision Medicine (SFPM) Virtual Monthly Seminar on October 14th at 11:30 am ET.

Dr. Margossian is leading SEngine’s clinical validation initiatives for the PARIS® Test, a CLIA certified cancer organoid based drug sensitivity test for all solid tumors. The presentation is entitled, “Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test,” and will highlight the data on the PARIS® Test, recently presented at the ASCO 2020 and ACCR 2020 annual meetings, inclusive of organoids sensitivity results, showing clinical correlation with genomics and previous clinical treatments. Registration for the live event is available for free at https://www.sfpm.io/seminars.php.

SFPM’s virtual monthly seminar brings together distinguished guest speakers and through interactive panel discussions and Q&A sessions focuses on these key topics:

  • Demonstrating the clinical utility of functional precision medicine testing
  • Implementing functional testing in precision medicine clinical trials
  • Accelerating the application of functional testing
  • Addressing stakeholder, educational and investment challenges for functional precision medicine

About PARIS® Test
The CLIA certified PARIS® Test is based on the capability to propagate patient-specific cancer tissue as organoids ex vivo and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where the path is not clear, such as many metastatic and recurrent cancers, the PARIS test provides crucial information to the treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine
SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:
Stephanie Carrington
[email protected]
646-277-1282

Source Article